Search results for "MATRICELLULAR PROTEIN"

showing 10 items of 14 documents

SPARC regulation of PMN clearance protects from pristane induced lupus and rheumatoid arthritis

2020

AbstractOne step along the pathogenesis of Systemic lupus erythematosus (SLE) is associated with polymorphonuclear leukocyte (PMN) death and their ineffective removal by M2-macrophages. The secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein with unexpected immunosuppressive function in M2-macrophages and myeloid cells. To investigate the role of SPARC in autoimmunity, we adopted a pristane–induced model of lupus in mice, which recapitulates clinical manifestations of human SLE. Sparc-/- mice developed earlier and more severe renal disease, lung and liver parenchymal damage than the WT counterpart. Most prominently, Sparc-/- mice had anticipated and severe occurr…

LungSystemic lupus erythematosusbusiness.industryMatricellular proteinArthritisDendritic cellmedicine.diseasemedicine.disease_causeAutoimmunityPathogenesismedicine.anatomical_structureRheumatoid arthritisImmunologymedicineCancer researchMacrophagebusiness
researchProduct

Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies

2014

Neoplastic B-cell clones commonly arise within secondary lymphoid organs (SLO). However, during disease progression, lymphomatous cells may also colonize the bone marrow (BM), where they localize within specialized stromal niches, namely the osteoblastic and the vascular niche, according to their germinal center-or extra-follicular-derivation, respectively. We hypothesized the existence of common stromal motifs in BM and SLO B-cell lymphoid niches involved in licensing normal B-cell development as well as in fostering transformed B lymphoid cells. Thus, we tested the expression of prototypical mesenchymal stromal cell (MSC) markers and regulatory matricellular proteins in human BM and SLO u…

Stromal cellImmunologylymphomalymphomasBiologybone marrow nicheB cell development; SPARC; bone marrow niches; lymphomas; microenvironmentStromaB cell developmentmedicineImmunology and AllergyLymphopoiesisB cellOriginal ResearchMesenchymal stem cellMatricellular proteinGerminal centerSPARCmedicine.diseasemicroenvironmentLymphomamedicine.anatomical_structureOncologyImmunologyCancer researchbone marrow nichesOncoImmunology
researchProduct

Intra-tumor heterogeneity of Diffuse Large B-cell Lymphoma involves the induction of diversified stroma-tumor interfaces

2020

ABSTRACTIntra-tumor heterogeneity in lymphoid malignancies is articulated around several fundamentals, encompassing selection of genetic subclonal events and epigenetic regulation of transcriptional programs. Clonally-related neoplastic cell populations are unsteadily subjected to immune editing and metabolic adaptations within different tissue microenvironments. How tissue-intrinsic mesenchymal determinants impact on the diversification of aggressive lymphomas is still unknown. In this study we adopted the established A20 line-based model of Diffuse Large B-cell Lymphoma (DLBCL), to investigate the intra-tumor heterogeneity associated with the infiltration of different tissue microenvironm…

Stromal cellStromahemic and lymphatic diseasesMatricellular proteinMesenchymal stem cellmedicineCancer researchNeoplastic cellEpigeneticsBiologymedicine.diseaseDiffuse large B-cell lymphomaLymphoma
researchProduct

Biological indicators of prognosis in Ewing's sarcoma: An emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP)

2009

Starting from an experimental model that accounts for the 2 most important adverse processes to successful therapy of Ewing's sarcoma (EWS), chemoresistance and the presence of metastasis at the time of diagnosis, we defined a molecular signature of potential prognostic value. Functional annotation of differentially regulated genes revealed 3 major networks related to cell cycle, cell-to-cell interactions and cellular development. The prognostic impact of 8 genes, representative of these 3 networks, was validated in 56 EWS patients. High mRNA expression levels of HINT1, IFITM2, LGALS3BP, STOML2 and c-MYC were associated with reduced risk to death and lower risk to develop metastasis. At mul…

Cancer ResearchMice NudeEnzyme-Linked Immunosorbent AssaySarcoma EwingBiologyMetastasisMiceAntigens NeoplasmCell Line TumorBiomarkers TumorCell AdhesionmedicineAnimalsHumansGene SilencingRNA MessengerNeoplasm MetastasisGlycoproteinsOligonucleotide Array Sequence AnalysisTumor microenvironmentReverse Transcriptase Polymerase Chain ReactionCell CycleMatricellular proteinEwing's sarcomaCell cyclePrognosismedicine.diseaseImmunohistochemistryOncologyTumor progressionImmunologyGalactoside bindingCancer researchSarcomaCarrier ProteinsSignal TransductionInternational Journal of Cancer
researchProduct

Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer.

2021

Abstract Fatal neuroendocrine differentiation (NED) of castration-resistant prostate cancer is a recurrent mechanism of resistance to androgen deprivation therapies (ADT) and antiandrogen receptor pathway inhibitors (ARPI) in patients. The design of effective therapies for neuroendocrine prostate cancer (NEPC) is complicated by limited knowledge of the molecular mechanisms governing NED. The paucity of acquired genomic alterations and the deregulation of epigenetic and transcription factors suggest a potential contribution from the microenvironment. In this context, whether ADT/ARPI induces stromal cells to release NED-promoting molecules and the underlying molecular networks are unestablis…

MaleCancer ResearchStromal cellAnimals Biomarkers Tumor Cell Differentiation Cell Line Tumor Coculture Techniques Endoplasmic Reticulum Chaperone BiP Epigenesis Genetic Gene Expression Regulation Neoplastic Humans Male Mice Mice Inbred C57BL Neuroendocrine Cells Osteonectin Prostatic Neoplasms Stromal Cells Transgenes Tumor Microenvironment Down-RegulationDown-RegulationContext (language use)Settore MED/08 - Anatomia PatologicaNeuroendocrine differentiationEpigenesis GeneticProstate cancerMiceStromaDownregulation and upregulationNeuroendocrine CellsCell Line TumormedicineBiomarkers TumorTumor MicroenvironmentSettore MED/05 - Patologia ClinicaAnimalsHumansOsteonectinEpigeneticsTransgenesEndoplasmic Reticulum Chaperone BiPbusiness.industryMatricellular proteinProstatic NeoplasmsCell Differentiationmedicine.diseaseCoculture TechniquesGene Expression Regulation NeoplasticMice Inbred C57BLOncologyCancer researchStromal CellsbusinessCancer research
researchProduct

Prognostic Relevance of CCN3 in Bone Sarcomas

2010

Osteosarcomas and Ewing’s sarcoma (EWS) are aggressive malignant bone tumors. In both cases, prognostic markers are lacking. Presently, only clinical features are widely accepted as prognostic indicators. In this study we assessed the prognostic value of CCN3 (Nov), a matricellular protein that belong to the CCN family of regulatory proteins, whose members were shown to play crucial roles in bone formation. In osteosarcomas, CCN3 expression levels represent a useful tool to early identification of patients with different prognosis. In both osteosarcomas and Ewing’s sarcomas, the expression of a full length CCN3 protein was associated to a worse prognostic and a higher risk to developing met…

integumentary systembusiness.industryMatricellular proteinEwing's sarcomaCcn familyBone Sarcomamedicine.diseaseMetastasismedicineCancer researchOsteosarcomaBone formationSarcomabusiness
researchProduct

Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces

2020

Abstract Background Intra-tumour heterogeneity in lymphoid malignancies encompasses selection of genetic events and epigenetic regulation of transcriptional programs. Clonal-related neoplastic cell populations are unsteadily subjected to immune editing and metabolic adaptations within different tissue microenvironments. How tissue-specific mesenchymal cells impact on the diversification of aggressive lymphoma clones is still unknown. Methods Combining in situ quantitative immunophenotypical analyses and RNA sequencing we investigated the intra-tumour heterogeneity and the specific mesenchymal modifications that are associated with A20 diffuse large B-cell lymphoma (DLBCL) cells seeding of d…

0301 basic medicinediffuse large B-cell lymphoma; digital spatial profiling; intra-tumour heterogeneity; microenvironment; SPARClcsh:MedicineMice0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesTumor MicroenvironmentIn Situ Hybridizationlcsh:R5-920Matricellular proteinGeneral MedicineDiffuse large B-cell lymphomaPrognosisGene Expression Regulation NeoplasticPhenotype030220 oncology & carcinogenesisLymphoma Large B-Cell Diffuselcsh:Medicine (General)Research PaperStromal cellMicroenvironmentTumour heterogeneityBiologySettore MED/08 - Anatomia PatologicaModels BiologicalGeneral Biochemistry Genetics and Molecular BiologyImmunophenotypingGenetic Heterogeneity03 medical and health sciencesImmune systemCell Line TumorBiomarkers TumormedicineAnimalsHumansEpigeneticsSequence Analysis RNAGene Expression Profilinglcsh:RMesenchymal stem cellComputational BiologySPARCDigital spatial profilingmedicine.diseaseIntra-tumour heterogeneityDisease Models Animal030104 developmental biologyCancer researchNeoplastic cellStromal CellsTranscriptomeDiffuse large B-cell lymphoma
researchProduct

Osteopontin shapes immunosuppression in the metastatic niche.

2014

Abstract The matricellular protein osteopontin (OPN, Spp-1) is widely associated with cancer aggressiveness when produced by tumor cells, but its impact is uncertain when produced by leukocytes in the context of the tumor stroma. In a broad study using Spp1−/− mice along with gene silencing in tumor cells, we obtained evidence of distinct and common activities of OPN when produced by tumor or host cells in a spontaneously metastatic model of breast cancer. Different cellular localization of OPN is associated with its distinct activities, being mainly secreted in tumor cells while intracellular in myeloid cells. OPN produced by tumor cells supported their survival in the blood stream, wherea…

STAT3 Transcription FactorCancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsosteopontinCellContext (language use)Breast NeoplasmsT-Lymphocytes RegulatoryMonocytesMicestomatognathic systemCell Line TumormedicineImmune ToleranceAnimalsHumansMyeloid CellsOsteopontinNeoplasm MetastasisCellular localizationImmunosuppression TherapyMice Inbred BALB CMice Inbred C3HimmunosuppressionbiologyArginaseInterleukin-6Matricellular proteinCancerosteopontin; niche; immunosuppressionmedicine.diseaseMice Inbred C57BLnichemedicine.anatomical_structureOncologyTumor progressionCell culturebiology.proteinFemale
researchProduct

SPARC regulation of PMN clearance protects from pristane-induced lupus and rheumatoid arthritis

2021

Summary The secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein with unexpected immunosuppressive function in myeloid cells. We investigated the role of SPARC in autoimmunity using the pristane-induced model of lupus that, in mice, mimics human systemic lupus erythematosus (SLE). Sparc−/− mice developed earlier and more severe renal disease, multi-organ parenchymal damage, and arthritis than the wild-type counterpart. Sparc+/- heterozygous mice showed an intermediate phenotype suggesting Sparc gene dosage in autoimmune-related events. Mechanistically, reduced Sparc expression in neutrophils blocks their clearance by macrophages, through defective delivery of don'…

0301 basic medicineScienceImmunologyArthritis02 engineering and technologySettore MED/08 - Anatomia Patologicamedicine.disease_causeArticleAutoimmunityPathogenesis03 medical and health sciencesmedicineSettore MED/05 - Patologia ClinicaMacrophageMolecular physiologyMultidisciplinarySystemic lupus erythematosusbusiness.industryQMatricellular proteinDendritic cell021001 nanoscience & nanotechnologymedicine.diseaseBiological sciences Immunology Molecular physiologyBiological sciences030104 developmental biologyRheumatoid arthritisCancer research0210 nano-technologybusinessiScience
researchProduct

WIN55,212-2-induced expression of Mir-29b1 favours the suppression of osteosarcoma cell migration in a SPARC-independent manner

2019

WIN55,212-2 (WIN) is a synthetic agonist of cannabinoid receptors that displays promising antitumour properties. The aim of this study is to demonstrate that WIN is able to block the migratory ability of osteosarcoma cells and characterize the mechanisms involved. Using wound healing assay and zymography, we showed that WIN affects cell migration and reduces the activity of the metalloproteases MMP2 and MMP9. This effect seemed to be independent of secreted protein acidic and rich in cysteine (SPARC), a matricellular protein involved in tissue remodeling and extracellular matrix deposition. SPARC release was indeed prevented by WIN, and SPARC silencing by RNA interference did not influence …

Cannabinoid receptorMorpholinesAntineoplastic AgentsMMP9NaphthalenesCatalysisArticlelcsh:ChemistryInorganic ChemistryExtracellular matrixExtracellular VesiclescannabinoidsDownregulation and upregulationCell MovementCell Line TumorSettore BIO/10 - BiochimicaGene silencingHumansOsteonectinCell migrationPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologyCannabinoidSpectroscopyCell ProliferationOsteosarcomaChemistryCell growthOrganic ChemistryMatricellular proteinCell migrationSPARCGeneral MedicineComputer Science ApplicationsCell biologyBenzoxazinesMiR-29b1MicroRNAslcsh:Biology (General)lcsh:QD1-999
researchProduct